



Influenza Update

TACKLE – Infection Prevention and Control Education Day

Hellenic Community Centre October 3, 2013



Presentation Outline

- Influenza in Middlesex-London 2012- 2013
 - Hilary Caldarelli, Contract Epidemiologist
- What's new in Influenza Immunization
 - Bryna Warshawsky, Associate Medical Officer of Health



Acknowledgements

- Alison Locker, Epidemiologist
- Tristan Squire-Smith, Manager,
 Infectious Disease Control Team
- Eleanor Paget, Public Health Nurse
- Sheila Montague, Public Health Nurse
- Infectious Disease Control Team
- Infection Control Practitioners in hospitals and long term care facilities



Influenza in Middlesex-London

- Comparison of recent seasons
- Cases by week of illness onset (epi curves)
- By season
- Hospitalizations by age
- Immunization status of cases by age
- Outbreaks
- By season, facility type
- Nosocomial cases




Influenza Statistics Overview, Middlesex-London

	2009- 2010	2010- 2011	2011- 2012	2012- 2013*
Laboratory- confirmed cases	391	276	106	477
Hospitalizations	92	161	34	301
Deaths	8	17	3	26
Outbreaks	2	28	6	40

^{*} Season to date as of August, 2013




2012-2013 Influenza A & B Epi Curve (N=477)



Source: IDC Database, extracted September 4, 2013




2011-2012 Influenza A & B Epi Curve (N=106)



Source: IDC Database, extracted June 5, 2012




2010-2011 Influenza A & B Epi Curve (N=276)



Source: IDC Database, extracted June, 2011




2012-13 Influenza Hospitalizations by age, n_h =302, Non-hospitalized, n_{nh} =175



Source: IDC Database, extracted June 21, 2013




2012-13 Influenza Immunization Status, N=392



Source: IDC Database, extracted June 21, 2013


2012-2013 Confirmed Influenza Outbreaks (N=40)



Source: IDC Database, extracted May 22, 2013

MIDDLESEX-LONDON HEALTH UNIT 2011-2012 Confirmed Influe


2011-2012 Confirmed Influenza Outbreaks (N=6)



Source: IDC Database, extracted April 23, 2013

MIDDLESEX-LONDON HEALTH UNIT


2010-2011 Confirmed Influenza Outbreaks (N=28)



Source: IDC Database, extracted April 23, 2013



2012-2013 Confirmed Influenza Outbreaks (N=40), by setting



Source: IDC Database, extracted May 22, 2013



Nosocomial Influenza Infections

- Any lab confirmed influenza infections that were diagnosed more than 72 hours after admission to an acute care inpatient unit are considered to be nosocomial
- 34 cases out of 477 met this definition (7%), all from London acute care settings
- 21 of the 34 nosocomial cases (62%) were associated with the nine hospital outbreaks
- 13 of the 34 nosocomial cases (38%) were not considered part of an outbreak



What's New in Influenza Immunization

- Recent NACI changes
 - Egg allergy
 - Preferential intranasal vaccine for children
 - Upcoming reviews
- Quadrivalent vaccines
- Vaccine effectiveness
- Age specific vaccines
- New methodologies for making flu vaccine
- H7N9 influenza
- Changes in when to call the coroner



Recent NACI Changes

Egg allergy



Egg Allergy – 2011-2012

- No longer a contraindication for trivalent inactivated influenza vaccine based on several studies
 - Still is for FluMist

 Very small amount of egg protein in vaccine < 1.2 micrograms / ml

MLHEALTH UNIT Egg Allergy – 2011-2012

- Lower risk for severe allergic reactions
 - Localized hives, gastrointestinal symptoms
 - Vaccinate at usual; keep 30 minutes
- Higher risk of severe allergic reactions
 - Generalized hives or respiratory or cardiovascular reactions, or poorly controlled asthma with egg allergy
 - Graded vaccination
 - 10 % of the dose; wait 30 minutes; give remaining 90% of dose; keep 30-60 minutes



NACI Changes – Egg Allergy

- Now recommending 0.5 ml for all
- Mild reactions such as hives
 - regular clinics
- Anaphylaxis with respiratory or cardiovascular symptoms
 - appropriate expertise and equipment to manage respiratory or cardiovascular compromise.
- Observe for 30 minutes



Influenza Vaccine Allergy

 Previous discussion applies to egg allergy

 Influenza vaccine allergy still a contraindication



Recent NACI Changes

Preferential Intranasal Vaccine for Children



- Live attenuated, intranasal vaccine
- 0.1 ml in each nostril (total 0.2 ml)
- Ages 2-59 years who are not immunocompromised
- NACI made preferential recommendations for children 2-17 years of age based on better efficacy in these children
- Re-looking at data regarding older children



FluMist Implementation

Limited use so far

Not publicly funded in Ontario

Cost about \$20.00 per dose

Not available at our clinics



NACI Changes

Upcoming Reviews Based on Different Age Groups



Age expansion

- 2012-2013 NACI recommended adding children 2 to < 5 years to high risk groups, as well as those who have close contact with them
- Based on elevated risk of hospitalization and outpatient visit and that source of community transmission
- Currently undertaking review of healthy:
 - 5 to 18 year olds
 - 19 to 64 year olds



Quadrivalent Vaccines




Quadrivalent Vaccines

- Contain H1N1, H3N2 and 2 B strains
- Live attenuated version and inactivated version available in the US
- Likely will be available in Canada next influenza season



- Affects all age groups, but mostly older children and adolescents
- Range from 1-44% of positive samples in 10 year period in US; average 24%
- 2 lineages have circulated globally:
 - B/Yamagata
 - B/Victoria
- 5 of 10 years, mismatch between vaccine and predominant circulating strain



Ambrose et al. Human Vaccines and Immunotherapeutics 8:1, 81-88; January 2012



This year's vaccine

- A/California/7/2009 (H1N1)-like virus,
- A/Victoria/361/2011 (A/Texas/50/2012)
- B/Massachusetts/2/2012–like (Yamagata lineage) virus.
- In US, Quadrivalent influenza:
 - B/Brisbane/60/2008—like (Victoria lineage) virus.



Vaccine Effectiveness

MIDDLESEX-LONDON HEALTH UNIT

Vaccine Effectiveness Controversy

- Osterholm Review:
 - Assessed 31 studies
 - TIV pooled efficacy 59% (95 % CI 51-67%) in 18-65 year olds
 - No TIV studies met inclusion criteria for other ages
 - LAIV pooled efficacy 83% (95% CI 69-91%) for 6 months to 7 year olds
 - No LAIV studies met inclusion criteria for older ages



CDC Vaccine Effectiveness Estimates for Outpatient Visits

- Overall effectiveness 56% (CI = 47%-63%)
- A (H3N2) 47% (CI = 35%–58%)
 - 58% for persons aged 6 months-17 years;
 - 46% for persons aged 18–49 years;
 - 50% for persons aged 50-64 years, and
 - 9% for persons aged ≥65 years
- B 67% (CI = 51%–78%)
 - 64% to 75% across age groups.




Age Specific Vaccines



Trying to get better efficacy

- FluMist (live, intranasal)
 - Better in children, but to what age?
- Fluad (MF59 adjuvanted vaccine)
 - May have better immunogenicity, uncertain if better efficacy and effectiveness in elderly
 - Better efficacy in children
- Intanza (intradermal vaccine) and Fluzone (high dose - 60 micrograms)
 - May have better immunogenicity, uncertain if better efficacy and effectiveness



Fluad

TIV without adjuvant

The cumulative efficacy of ATIV and of TIV, as compared with control (non-

influenza) vaccine, is shown. The data are for efficacy against all viral strains over time after the second dose of vaccine in children 6 to less than 72 months of age. Shaded areas represent 95% confidence intervals.

Fluad (MF59 adjuvant) in children 6 to 72 months



New Methodologies for Making Flu Vaccine



Flucelvax

- Cell-culture based vaccine (Novartis)
- Available in US for 18 years of age and over
- Not grown in egg; so very little egg protein



FluBlock

- Recombinant hemagglutinin Vaccine (Protein Science)
- Available in US for 18 to 49 years
- Put hemagluttinin gene into baculovirus
- Highly specific to insect cells
- Infect insect cells with virus
- Incubate in ~48-72 hours
- Purify resulting protein



FluBlock

- Uses larger amounts of hemagluttinin per strain (45 micrograms per strain)
- No egg
- From gene to production in 21 days
- Pandemic solution



H7N9 Influenza



H7N9 Influenza

- 136 cases, 44 deaths since February 2013
- All arose in Eastern China
- Middle aged and elderly men
- Believed to be attributed to contact with live bird markets; Limited person to person spread
- Under control due to culling birds in live bird markets and/or seasonal factors
- Candidate influenza vaccine viruses available



Changes in When to Call the Coroner



Used to Notify the Coroner

- Every death via electronic Institutional Patient Death Record (IPDR)
- Called if met Section 10 of Coroners Act
- Called if every 10th death in long-term care facility
- Called if death during an outbreak



Now Notify the Coroner

- As of September 16, 2013:
 - Still fill out the Institutional Patient Death Record
 - Still notify if meets Section 10 of Coroners
 Act
- Coroner does not need to be notified of:
 - Deaths during outbreak
 - Every 10th death



Health Unit Needs to be Notified

- Health Unit should be notified of all deaths during an outbreak (whether obviously outbreak related or not)
- Staff member will discussion situations of concern with on-call physician
- Will decide if need to notify the coroner e.g.
 - Cluster of deaths
 - Need assistance determining the cause of the outbreak